Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study

BMC Infectious Diseases volume 23, Article number: 707 (2023) Cite this article

Abstract

Background

This study’s objective was to investigate the predictors for severe anemia, severe leukopenia, and severe thrombocytopenia when amphotericin B deoxycholate-based induction therapy is used in HIV-infected patients with talaromycosis.

Methods

A total of 170 HIV-infected patients with talaromycosis were enrolled from January 1st, 2019, to September 30th, 2020.

Results

Approximately 42.9%, 20.6%, and 10.6% of the enrolled patients developed severe anemia, severe leukopenia, and severe thrombocytopenia, respectively. Baseline hemoglobin level < 100 g/L (OR = 5.846, 95% CI: 2.765 ~ 12.363), serum creatinine level > 73.4 µmol/L (OR = 2.573, 95% CI: 1.157 ~ 5.723), AST/ALT ratio > 1.6 (OR = 2.479, 95% CI: 1.167 ~ 5.266), sodium level ≤ 136 mmol/liter (OR = 4.342, 95% CI: 1.747 ~ 10.789), and a dose of amphotericin B deoxycholate > 0.58 mg/kg/d (OR = 2.504, 95% CI:1.066 ~ 5.882) were observed to be independent risk factors associated with the development of severe anemia. Co-infection with tuberculosis (OR = 3.307, 95% CI: 1.050 ~ 10.420), and platelet level (per 10 × 109 /L) (OR = 0.952, 95% CI: 0.911 ~ 0.996) were shown to be independent risk factors associated with the development of severe leukopenia. Platelet level < 100 × 109 /L (OR = 2.935, 95% CI: 1.075 ~ 8.016) was identified as the independent risk factor associated with the development of severe thrombocytopenia. There was no difference in progression to severe anemia, severe leukopenia, and severe thrombocytopenia between the patients with or without fungal clearance at 2 weeks. 10 mg on the first day of amphotericin B deoxycholate was calculated to be independent risk factors associated with the development of severe anemia (OR = 2.621, 95% CI: 1.107 ~ 6.206). The group receiving a starting amphotericin B dose (10 mg, 20 mg, daily) exhibited the highest fungal clearance rate at 96.3%, which was significantly better than the group receiving a starting amphotericin B dose (5 mg, 10 mg, 20 mg, daily) (60.9%) and the group receiving a starting amphotericin B dose (5 mg, 15 mg, and 25 mg, daily) (62.9%).

Conclusion

The preceding findings reveal risk factors for severe anemia, severe leukopenia, and severe thrombocytopenia. After treatment with Amphotericin B, these severe adverse events are likely unrelated to fungal clearance at 2 weeks. Starting amphotericin B deoxycholate at a dose of 10 mg on the first day may increase the risk of severe anemia but can lead to earlier fungal clearance.

Trial registration

ChiCTR1900021195. Registered 1 February 2019.

Peer Review reports

Background

Talaromyces marneffei, a prevalent dimorphic fungus among people living with HIV/AIDS in China (prevalence ranging from 3.3 to 15%) [1, 2], has a mortality rate of up to 30% [3], particularly in older patients [4], despite appropriate anti-fungal treatment. Anemia is commonly present in HIV-infected patients with talaromycosis, and its prevalence is between 80 and 95.6% [5, 6]. This could lead to negative outcomes, such as prolonged hospitalization, a requirement for close monitoring, and eventually the requirement for blood or platelet transfusion [7]. Thrombocytopenia and anemia are both independent risk factors for poor prognosis in HIV-infected patients with comorbid talaromycosis [8,9,10]. Moreover, platelets have been shown to possess antimicrobial activity against bacteria, viruses, and fungi [11, 12]. Leukopenia occurs in approximately 40% of HIV-infected patients with talaromycosis [5], and can weaken the host immune system, increasing the susceptibility of patients to opportunistic infections [8]. This susceptibility may ultimately impact the progression of HIV-associated talaromycosis. Currently, it is unclear which risk factors predict the development of severe anemia, severe leukopenia, and severe thrombocytopenia in HIV-infected patients with talaromycosis, particularly in those undergoing treatment with amphotericin B deoxycholate.

Current guidelines recommend amphotericin B deoxycholate as the preferred induction therapy for talaromycosis. An open-label, non-inferiority trial conducted in Vietnam found that amphotericin B deoxycholate was superior to itraconazole as initial treatment [3]; however, the toxic effects of amphotericin B deoxycholate, such as anemia, leukopenia, and thrombocytopenia, cannot be ignored [13, 14]. Up to 40% of HIV-infected patients with talaromycosis, whether with anemia or not at baseline, develop severe anemia after they have initiated amphotericin B deoxycholate [3]. The incidence of patients who started amphotericin B deoxycholate and subsequently developed severe leukopenia and severe thrombocytopenia is approximately 10% and 20%, respectively [3]. We recently completed a prospective multicenter cohort study evaluate efficacy and safety of voriconazole versus amphotericin B deoxycholate induction treatment for HIV-Associated talaromycosis [15]. Up to 45% of HIV-infected patients with talaromycosis in the amphotericin B deoxycholate group had a hemoglobin level below 74 g/L, which is higher than the voriconazole group. We are uncertain whether the decrease in hemoglobin, leukopenia, and thrombocytopenia observed in HIV-infected patients with talaromycosis treated with amphotericin B deoxycholate is caused by the fungi or amphotericin B deoxycholate. The risk factors which predict severe anemia, severe leukopenia, and severe thrombocytopenia in HIV-infected patients comorbid with talaromycosis being treated with amphotericin B deoxycholate are unknown. We, therefore, use data from a multi-center prospective observational study to assess risk factors for the occurrence of severe anemia, leukopenia, and thrombocytopenia in HIV-infected patients being treated with amphotericin B deoxycholate for talaromycosis.

Methods

Study design and setting

This was a prospective, multi-center, observational study of HIV-infected patients with talaromycosis who were admitted to hospitals between January 1st, 2019, and September 30th, 2020. The study enrolled patients from 11 hospitals located in 9 cities, namely: Chongqing Public Health Medical Center, Guangzhou Eighth People’s Hospital, Guangxi Longtan Hospital of Guangxi Zhuang Autonomous Region, Liuzhou General Hospital, the Third People’s Hospital of Guilin, the First Hospital of Changsha, the Fourth People’s Hospital of Nanning, Kunming Third People’s Hospital, Guiyang Public Health Clinical Center, Beijing Youan Hospital of Capital Medical University, and Yunnan Provincial Infectious Disease Hospital. Eligible patients were adults aged 18 years or older with confirmed HIV infection and confirmed talaromycosis by either microscopy or culture. Exclusion criteria included patients with hematologic diseases causing anemia (including aplastic anemia, hemolytic anemia, bleeding, and so on), severe active infections caused by bacteria or other microbes, tumors, hemoglobin levels less than 80 g/L, leukocyte counts less than 1.0 × 109/L, neutrophil counts less than 0.5 × 109/L, platelet counts less than 30 × 109/L, blood amylase levels greater than 2 times the upper limit of the reference level, serum creatinine levels greater than 1.5 times the upper limit of the reference level, aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase levels greater than 5 times the upper limit of the reference level, total bilirubin levels greater than 2 times the upper limit of the reference level, and serum creatine phosphokinase (CK) levels greater than 2 times the upper limit of the reference level. Patients received treatment with amphotericin B deoxycholate for 14 days at a dose of 0.5 to 0.7 mg per kilogram per day, starting with smaller doses of amphotericin B deoxycholate (5 to 10 mg once a day) and gradually increasing the dose by 5 to 10 mg/day to the final daily dose. Written informed consent was obtained from all patients or their representatives. The independent ethics committees of each participating hospital approved the trial protocol.

Assessments

We explored demographic factors, symptoms and signs, diagnosis of opportunistic infections, laboratory test results at admission, and types of combination antiretroviral therapy before diagnosis of talaromycosis. Each individual was invited to participate in 2-weeks of follow-up. At the follow-up visits at weeks 1, 2, hemoglobin, platelets, and leukocytes were evaluated.

Outcomes and definitions

Patients were evaluated for hematological toxicity, including anemia, leukopenia, and thrombocytopenia at weeks 1 and 2 after the initiation of amphotericin B deoxycholate. The primary outcome was the occurrence of severe hematological toxicity due to any cause, defined as the appearance of at least one of three laboratory abnormalities during amphotericin B deoxycholate treatment [14]. Severe anemia was defined as hemoglobin level drop to 80 g/L. Severe leukopenia was defined as leukocyte count drop to 2 × 109 /L or, if baseline count was under 2 × 109 /L, a decrease of 25% in leukocyte count. Severe thrombocytopenia was defined as platelet count decrease to 50 × 109 /L, or, if the baseline count was under 50 × 109 /L, a decrease of 25% in platelet count.

Weight loss was defined as loss of more than 10% of body weight within 6 months. All patients were tested for tuberculosis, cytomegalovirus infection, syphilis, hepatitis B, and hepatitis C. These diagnoses were confirmed according to laboratory testing results. A large fraction of the diagnoses for pneumocystis pneumonia, oral candidiasis, and toxoplasma encephalopathy were presumptive, due to easier establishment of a clinical diagnosis and the limited availability of definitive pathogenic testing for these specific diseases.

Statistical analysis

Statistical Package for the Social Sciences software, Version 25.0 (IBM-SPSS Statistics, Armonk, New York, USA) was used to analyze all study data. Standard descriptive statistics analyzed the clinical characteristics, diagnosis, and laboratory variables of patients. Continuous variables and categorical variables were compared using the Mann-Whitney U test and Chi-squared tests, respectively. Continuous variables with a p-value of ≤ 0.1, such as BMI, serum creatinine, AST/ALT, sodium, and potassium in the analysis of severe anemia and platelet level in the analysis of severe leukopenia were converted to categorical variables by grouping values using cut-off points based on a receiver-operating characteristic curve (ROC). Continuous variables with a p-value of ≤ 0.1, such as hemoglobin levels, platelet counts, and potassium levels in the analysis of severe anemia were converted into categorical variables by clinically relevant values. In identifying independent factors associated with severe anemia, severe leukopenia, or severe thrombocytopenia, variables were initially analyzed using a bivariate model, and subsequently independent risk factors were identified by means of a logistic regression model using a forward, stepwise approach, which began with inclusion of all variables associated with severe anemia, severe leukopenia, or severe thrombocytopenia on bivariate analysis (p ≤ 0.1), and subsequently included only those variables with p ≤ 0.05 in the final model. We used the variance inflation factor (VIF) and tolerance value of each univariate predictor to make the Multicollinearity diagnosis. If the VIF was higher than 10.0 and the tolerance is lower than 0.1, the variable would not have been included in the multivariate analysis.

Results

During the study, 414 patients were evaluated for eligibility, and 170 of them were included (Fig. 1). 73 of 170 patients (42.9%) developed severe anemia, 35 of 170 patients (20.6%) developed severe leukopenia, and 18 of 170 patients (10.6%) developed severe thrombocytopenia after starting amphotericin B deoxycholate.

Fig. 1
figure 1

Study flowchart

Full size image

Table 1 shows baseline characteristics for patients. Compared with patients without severe anemia, more patients developed severe anemia had a lower BMI, weight loss, a lower hemoglobin level, a lower platelet level, a higher serum creatinine level, a higher AST/ALT ratio, a lower sodium level, and an induction therapeutic dose of amphotericin B deoxycholate of > 0.58 mg/kg/d (Tables 1 and 2). Compared with patients who did not develop severe thrombocytopenia, more patients developed severe thrombocytopenia had lower baseline platelet levels (Table 3).

Table 1 Clinical characteristics of the patients developing severe anemia or not at baseline
Full size table
Table 2 Clinical characteristics of the patients developing severe leukopenia or not at baseline
Full size table
Table 3 Clinical characteristics of the patients developing severe thrombocytopenia or not at baseline
Full size table

Multivariate logistic regression analysis revealed that hemoglobin levels < 100 g/L (OR = 5.846, 95% CI: 2.765 ~ 12.363), serum creatinine levels > 73.4 µmol/L (OR = 2.573, 95% CI: 1.157 ~ 5.723), AST/ALT ratio > 1.6 (OR = 2.479, 95% CI: 1.167 ~ 5.266), sodium level ≤ 136 mmol/liter (OR = 4.342, 95% CI: 1.747 ~ 10.789), and a dose of amphotericin B deoxycholate > 0.58 mg/kg/d (OR = 2.504, 95% CI:1.066 ~ 5.882) were independent risk factors associated with the development of severe anemia (Table 4).

Table 4 Univariate and multivariate analysis of factors associated with severe anemia, severe leukopenia and severe thrombocytopenia for the outcome of HIV-infected patients complicated with talaromyces marneffei infection
Full size table

Patients co-infected with tuberculosis and those who had lower platelet levels were shown to be at higher risk of progression to severe leukopenia (p ≤ 0.1). Co-infection with tuberculosis (OR = 3.307, 95% CI: 1.050 ~ 10.420), and platelet level (per 10 × 109 /L) (OR = 0.952, 95% CI: 0.911 ~ 0.996) were calculated to be independent risk factors associated with the development of severe leukopenia (Table 4).

Male gender and platelet levels lower than 100 × 109 /L were identified as risk factors associated with progression to severe thrombocytopenia (p ≤ 0.1). Platelet levels < 100 × 109 /L (OR = 2.935, 95% CI: 1.075 ~ 8.016) was identified as the independent risk factor associated with the development of severe thrombocytopenia (Table 4).

There was no difference in progression to severe anemia, severe leukopenia, and severe thrombocytopenia between the survivors and non-survivors. There was also no difference between the patients without fungal clearance and with fungal clearance at 2 weeks (Table 5).

Table 5 Outcomes of the patients developing severe anemia, leukopenia, or thrombocytopenia or not at 2 weeks
Full size table

Eighty-seven patients used that the started dosing for Amphotericin B is 5 mg on the first day, 10 mg on the second day, 20 mg on the third day, and the therapeutic dose is reached on the fourth day. Thirty-five patients used the started dosing for Amphotericin B is 5 mg on the first day, 15 mg on the second day, 25 mg on the third day, and the therapeutic dose is reached on the fourth day. Twenty-seven patients used the started dosing for Amphotericin B is 10 mg on the first day, 20 mg on the second day, and the therapeutic dose is reached on the third day. Comparing with 5 mg on the first day group, 10 mg on the first day group (10 mg, 20 mg, daily) were calculated to be independent risk factors associated with the development of severe anemia (OR = 2.621, 95% CI: 1.107 ~ 6.206) (Table 6).

Table 6 Univariate analysis of factors associated with severe anemia, severe leukopenia, and severe thrombocytopenia in 149 patients
Full size table

The group receiving a starting amphotericin B dose (10 mg, 20 mg, daily) exhibited the highest fungal clearance rate at 96.3% (26/27), which was significantly better than the group receiving a starting amphotericin B dose (5 mg, 10 mg, 20 mg, daily) (60.9%) and the group receiving a starting amphotericin B dose (5 mg, 15 mg, 25 mg, daily) (62.9%). No significant differences were observed among the three groups in terms of progression to severe anemia, severe leukopenia, or severe thrombocytopenia at 2 weeks, as well as survival at both 2 weeks and 48 weeks (Table 7).

Table 7 Outcomes of three amphotericin B starting regimens at 2 weeks and 48 weeks in 149 patients
Full size table

Figure 2 shows the changes in hemoglobin levels over time were compared between the group without severe anemia and the group with progression to severe anemia. At baseline, week 1, and week 2, the group that progressed to severe anemia had lower hemoglobin levels compared to the group without severe anemia (median hemoglobin level 91.46 g/L [95% CI, 95.05–87.87 g/L] vs. 106.39 g/L [95% CI, 103.25-109.53 g/L], p < 0.001; 70.74 g/L [95% CI, 68.43–73.05 g/L] vs. 98.54 g/L [95% CI, 96.05-101.02 g/L], p < 0.001; 71.28 g/L [95% CI, 68.28–74.28 g/L] vs. 92.58 g/L [95% CI, 89.63–95.53 g/L], p < 0.001). Eleven patients had hemoglobin levels below 60 g/L within 14 days. Six people changed amphotericin B deoxycholate to other antifungal medications within 14 days, and the median day was day 10 (95% CI: 7.42–12.57 days), but the reason for changing medication was not severe anemia, severe leukopenia, and severe thrombocytopenia. At week 4, the median hemoglobin level of the group that progressed to severe anemia was 87.12 g/L (95% CI, 81.70-92.55 g/L).

Fig. 2
figure 2

The changes in hemoglobin levels over time were compared between the group without severe anemia and the group with progression to severe anemia. * < 0.05, ** < 0.01, *** < 0.001

Full size image

Discussion

Our results observed that the incidence of patients who developed severe anemia, severe leukopenia, and severe thrombocytopenia were 42.9%, 20.6%, and 10.6%, respectively, which approximates the observations of one previous prospective study [3].

A higher AST/ALT level, lower hemoglobin level, higher serum creatinine level, lower sodium level, and a higher administered dose of amphotericin B were found to be independent risk factors for development of severe anemia. AST and ALT are mainly produced in liver cells and are also the main circulating hepatic enzymes in serum. Blood AST and ALT levels could increase as a consequence of hepatocellular damage or hepatic cellular death [3]. Patients with talaromycosis can present with systemic infection, including that of the liver. Thus, hepatic transaminases are often elevated in patients with talaromycosis [16]. One study even observed that a higher AST/ALT ratio increased the risk of death in HIV-infected patients with talaromycosis [1]. However, to our knowledge, no study has investigated the connection between anemia and AST/ALT ratio in HIV-infected patients with talaromycosis. This phenomenon of higher values of AST/ALT associated with a higher prospective risk of severe anemia might be associated with abnormalities in the composition of red blood cell membranes or the limitation of effective bone marrow erythropoiesis, which are known causes of anemia associated with liver disease. Higher serum creatinine levels and lower sodium level are known to be associated with impaired renal function [17]. The preceding study observed that HIV infection and impaired renal function can result in a higher risk of anemia, which concurs with results of our study, as both HIV infection and impaired renal function have a synergistic impact on lowering hemoglobin levels [18]. The adverse effects of Amphotericin B occurs in a dose-dependent manner [13]. This means that higher doses of amphotericin B are associated with a higher risk of adverse effects, which is precisely what we observed in our study. It is, thus, important to establish a balance between maximizing antifungal efficacy and minimizing drug-related toxicity [19].

Patients co-infected with tuberculosis are associated with severe leukopenia. The possible reason for this is that anti-tuberculosis drugs may promote antibody generation and form antigen-antibody complexes which may be absorbed on to leukocytes, and cause leukocyte lysis and damage [20, 21]. Many previous studies have shown that baseline thrombocytopenia is associated with poor prognosis [5, 22]. However, the reason why lower platelet levels at baseline are also associated with severe leukopenia is still unclear.

Lower platelets levels at baseline were found to be associated with the development of severe thrombocytopenia. Talaromycosis itself, together with the toxic effects of amphotericin B deoxycholate, may both promote the development of severe thrombocytopenia. The progression of severe thrombocytopenia is associated with an increased risk of hemorrhage. Discontinuation of the causative drug should sometimes be considered, if necessary.

There was also no difference between the patients without fungal clearance and with fungal clearance at 2 weeks. This means that although decreased baseline hemoglobin, platelets, and white blood cells each are associated with poor prognosis, this does not imply that these severe events are not effectively treated with amphotericin B deoxycholate. The adverse effects of Amphotericin B occur in a dose-dependent manner. Our findings indicate that the group receiving 10 mg on the first day had a higher likelihood of developing severe anemia compared to the group receiving 5 mg on the first day. This suggests that the anemia is likely related to the drug. The majority of patients had completed the 2-week induction therapy based on amphotericin B deoxycholate and stopped amphotericin B deoxycholate at week 2. The group that progressed to severe anemia had a median hemoglobin level of 71.28 g/L [95% CI, 68.28–74.28 g/L] at week 2, which increased to 87.12 g/L (95% CI, 81.70-92.55 g/L) by week 4. This also suggests that the occurrence of anemia may be related to amphotericin B deoxycholate. The erythropoietin suppression by amphotericin B has been proposed to contribute to the development of anemia [23]. we regretted that markers of erythropoietin were not tested.

Starting amphotericin B deoxycholate at a dose of 10 mg on the first day seems to increase the risk of severe anemia but can lead to earlier fungal clearance. If patients are not at risk of developing severe anemia, starting amphotericin B dose (10 mg, 20 mg, daily) is more likely to be beneficial.

This is a subgroup analysis of a prospective multicenter cohort study. Study limitations include missing markers of disseminated intravascular coagulation, hemopoietin, reticulocyte and serum drug concentration determinations, data of some people on the dose escalation of amphotericin B deoxycholate, an exclusively Chinese study cohort, and some seriously ill patients having to be excluded from the study, which limits our study’s overall generalizability.

Conclusions

The preceding findings reveal risk factors for severe anemia, severe leukopenia, and severe thrombocytopenia. After treatment with Amphotericin B, these severe adverse events are likely unrelated to fungal clearance at 2 weeks. 5 mg on the first day of amphotericin B deoxycholate seems to be able to lower the risk of severe anemia. These findings may contribute to the development of effective prevention and management strategies for patients who are at risk of developing these severe adverse events.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Qin Y, Zhou Y, Lu Y, Chen H, Jiang Z, He K, et al. Multicentre derivation and validation of a prognostic scoring system for mortality assessment in HIV-infected patients with talaromycosis. Mycoses. 2021;64(2):203–11.

    Article  CAS  PubMed  Google Scholar 

  2. Qin Y, Huang X, Chen H, Liu X, Li Y, Hou J, et al. Burden of Talaromyces marneffei infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):551.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Le T, Kinh NV, Cuc NTK, Tung NLN, Lam NT, Thuy PTT, et al. A trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. N Engl J Med. 2017;376(24):2329–40.

    Article  CAS  PubMed  Google Scholar 

  4. Zhou Y, Yang Z, Liu M, Lu Y, Qin Y, He X, et al. Independent risk factors for deaths due to AIDS in Chongqing, China: does Age Matter? Front Med (Lausanne). 2020;7:586390.

    Article  PubMed  Google Scholar 

  5. Ying RS, Le T, Cai WP, Li YR, Luo CB, Cao Y, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011–2017. HIV Med. 2020;21(11):729–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ranjana KH, Priyokumar K, Singh TJ, Gupta Ch C, Sharmila L, Singh PN, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect. 2002;45(4):268–71.

    Article  CAS  PubMed  Google Scholar 

  7. Brandriss MW, Wolff SM, Moores R, Stohlman F. Jr. Anemia induced by amphotericin B. JAMA. 1964;189:663–6.

    Article  CAS  PubMed  Google Scholar 

  8. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7):27s–43s.

    Article  PubMed  Google Scholar 

  9. Albrecht S, Franzeck FC, Mapesi H, Hatz C, Kalinjuma AV, Glass TR, et al. Age-related comorbidities and mortality in people living with HIV in rural Tanzania. Aids. 2019;33(6):1031–41.

    Article  PubMed  Google Scholar 

  10. Haider BA, Spiegelman D, Hertzmark E, Sando D, Duggan C, Makubi A, et al. Anemia, Iron Deficiency, and Iron Supplementation in Relation to Mortality among HIV-Infected patients receiving highly active antiretroviral therapy in Tanzania. Am J Trop Med Hyg. 2019;100(6):1512–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis. 1997;25(5):951–68. quiz 69–70.

    Article  CAS  PubMed  Google Scholar 

  12. Madzime M, Rossouw TM, Theron AJ, Anderson R, Steel HC. Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Front Immunol. 2021;12:634386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lemke A, Kiderlen AF, Kayser O, Amphotericin B. Appl Microbiol Biotechnol. 2005;68(2):151–62.

    Article  CAS  PubMed  Google Scholar 

  14. Falci DR, da Rosa FB, Pasqualotto AC. Hematological toxicities associated with amphotericin B formulations. Leuk Lymphoma. 2015;56(10):2889–94.

    Article  CAS  PubMed  Google Scholar 

  15. Zhou Y, Qin Y, Lu Y, et al. Efficacy and safety of Voriconazole Versus amphotericin B deoxycholate induction treatment for HIV-Associated Talaromycosis: a prospective Multicenter Cohort Study in China. Infect Dis Ther. 2022;11(4):1575–90.

    PubMed  PubMed Central  Google Scholar 

  16. Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011;52(7):945–52.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kannapiran M, Nisha D, Madhusudhana Rao A. Underestimation of impaired kidney function with serum creatinine. Indian J Clin Biochem. 2010;25(4):380–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Abraham AG, Palella FJ, Li X, Estrella MM, Kingsley LA, Witt MD, et al. The impact of impaired kidney function and HIV infection on the risk of anemia. AIDS Res Hum Retroviruses. 2012;28(12):1666–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Le T, Ly VT, Thu NTM, Nguyen A, Thanh NT, Chau NVV, et al. Population Pharmacodynamics of Amphotericin B Deoxycholate for disseminated infection caused by Talaromyces marneffei. Antimicrob Agents Chemother. 2019;63(2):e01739-18.

  20. De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998;31(1):108–15.

    Article  PubMed  Google Scholar 

  21. Lin FS, Wu MY, Tu WJ, Pan HQ, Zheng J, Shi JW, et al. A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis treatment. J Thorac Dis. 2015;7(12):2234–42.

    PubMed  PubMed Central  Google Scholar 

  22. Shi M, Lin J, Wei W, et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China. PLoS Negl Trop Dis. 2022;16(5):e0010388.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Yeo EJ, Ryu JH, Cho YS, et al. Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood. 2006;107(3):916–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We express our sincere thanks and gratitude to all medical personnel, including clinical fellows, nurses, and cleaners of 11 hospitals from around China, viz., Chongqing Public Health Medical Center, Guangzhou Eighth People’s Hospital, Guangxi Longtan Hospital of Guangxi Zhuang Autonomous Region, Liuzhou General Hospital, the Third People’s Hospital of Guilin, the First Hospital of Changsha, the Fourth People’s Hospital of Nanning, Kunming Third People’s Hospital, Guiyang Public Health Clinical Center, Beijing Youan Hospital of Capital Medical University, Yunnan Provincial Infectious Disease Hospital, and Affiliated Hospital of Zunyi Medical University for their valuable support and contributions during study period. We thank all study participants and everyone who contributed to the recruitment and follow-up of participants.

Funding

The trial was funded by: the National Science and Technology Major Project of China during the 13th Five-year plan period (No. 2018ZX10302104), the medical scientific research project of Chongqing Health Commission (No.2022WSJK037), the Joint Medical Research Projects of Chongqing Municipal Health Committee and Chongqing Municipal Science and Technology Bureau (No.2020MSXM097, No.2022QNXM032, No.2020FYYX066, No.2020FYYX161, No.2018MSXM013), the Chinese National Natural Science Foundation Project (No.81860114), The funding bodies have had no role in the trial design, trial execution, collection and interpretation of data, manuscript writing and editing, or decision to submit for publication.

Author information

Author notes

  1. Yihong Zhou, Tao Lu, Shide Lin and Yaokai Chen contributed equally to this work.

Authors and Affiliations

  1. Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Guizhou, China

    Yihong Zhou, Tao Lu & Shide Lin

  2. Division of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China

    Yihong Zhou, Yuanyuan Qin, Yanqiu Lu, Vijay Harypursat & Yaokai Chen

  3. School of Public Health, Zunyi Medical University, Guizhou, China

    Yan Li & Yaokai Chen

  4. Division of Infectious Diseases, the Third People’s Hospital of Guilin, Guangxi, China

    Qun Tian

  5. Division of Infectious Disease, Longtan Hospital of Guangxi Zhuang Autonomous Region, Guangxi, China

    Ke Lan

  6. Division of Infectious Diseases, the First Hospital of Changsha, Hunan, China

    Guoqiang Zhou

  7. Division of Infectious Diseases, the Fourth People’s Hospital of Nanning, Guangxi, China

    Yingmei Qin

  8. Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Guangxi, China

    Shunmei Li

  9. College of Laboratory Medicine, Zunyi Medical University, Zunyi, China

    Shide Lin

Authors
  1. Yihong Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuanyuan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanqiu Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qun Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ke Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Guoqiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yingmei Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Vijay Harypursat
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Shunmei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shide Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yaokai Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YC, SL, and YZ designed and implemented the study. TL and SL were involved in data collection. YL did the statistical analyses. QT, KL, GZ, and YQ organized investigational procedures at the different study sites. YC, SL, and YZ interpreted the data and wrote the manuscript. YQ and YL were responsible for data management and quality control of baseline investigation at the different study sites. VH revised, copy-edited, and proofread the manuscript. All contributing authors read and approved the final version of the manuscript.

Corresponding authors

Correspondence to Shide Lin or Yaokai Chen.

Ethics declarations

Ethics approval and consent to participate

The independent ethics committee of each participating hospital approved the trial protocol (Chongqing Public Health Medical Center, Beijing Youan Hospital of Capital Medical University, Harbin Medical University, the First Hospital of Changsha, Guangzhou Eighth People’s Hospital, Liuzhou General Hospital, the Third People’s Hospital of Guilin, the Third People’s Hospital of Shenzhen, Guiyang Public Health Clinical Center, Kunming Third People’s Hospital, Yunnan Provincial Infectious Disease Hospital, the Fourth People’s Hospital of Nanning, Guangxi Longtan Hospital, the First Affiliated Hospital of Zhejiang University, and Xixi Hospital of Hangzhou). The study was performed in accordance with the Helsinki Declaration of 1964,and its later amendments. Informed consent was obtained from all individual participants included in the study.

Consent for publication

All of authors agree to submit the manuscript for possible publication.

Competing interests

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., Lu, T., Li, Y. et al. Severe anemia, severe leukopenia, and severe thrombocytopenia of amphotericin B deoxycholate-based induction therapy in patients with HIV-associated talaromycosis: a subgroup analysis of a prospective multicenter cohort study. BMC Infect Dis 23, 707 (2023). https://doi.org/10.1186/s12879-023-08394-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12879-023-08394-7

Keywords

BMC Infectious Diseases

ISSN: 1471-2334

Contact us